Hiromichi Nakajima

5PUBLICATIONS
60CO-AUTHORS
Immunogenetics (incl. genetic immunology)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 07, 2026
Incidence, Clinical Characteristics, Management, and Outcomes of Hematologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors: A Single-Center Japanese Retrospective Cohort Study.

|Aug 07, 2026
cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer.

|Jul 25, 2026
Outcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis.

|Apr 02, 2025
Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer.

Mao Uematsu, Hiromichi Nakajima, Hirohiko Miyake

|Feb 21, 2022
Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy.

Yoshiaki Nakamura, Wataru Okamoto, Tadamichi Denda

Pageof 1

Frequent Collaborators

3 joint publications

Kenichi Harano

2 joint publications

Yoshiaki Nakamura

2 joint publications

Takao Fujisawa

2 joint publications

Hideaki Bando